INTRODUCTION
Some patients with unexplained viral pneumonia were reported in Wuhan, a city in the Hubei Province of China, at the end of 2019. Following its identification as a novel coronavirus pathogen (SARS-CoV-2) and an increasing number of cases in many countries, especially in Europe, World Health Organization (WHO) declared the COVID-19 as a pandemic on March 11, 2020.1 In this process, many data show that COVID-19 should be considered as a systemic disease, including respiratory, neuromuscular, cardiovascular, dermatological, immune and hematological systems.2,3 Therefore, in addition to treatment guidelines of COVID-19, various management guidelines related to specific divisions have been published from diverse societies and centers.4-6
Some studies reported that patients who were diagnosed with cancer and also immunosuppressed have a significantly higher risk of infection with SARS-CoV-2.7,8 Although the infection does not have any specific clinical findings, several hematological findings, such as lymphopenia, thrombocytopenia, prolonged coagulation tests, increased fibrin degradation products and increased ferritin levels, were also defined in patients who are virus-infected.5
To our knowledge, there was no study evaluated hematology consultation in the COVID-19 era in the literature. Herein, we aimed to present features of patients who consulted the hematology unit in this term.